CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
“Even though CTLA4 is expressed by activated CD8 + effector T cells, the major physiological role of CTLA4 seems to be through distinct effects on the two major subsets of CD4 + T cells: downmodulation of helper T cell activity and enhancement of regulatory T (T Reg ) cell immunosuppressive activit”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
“Beyond its role in dampening activation of effector T cells, CTLA-4 plays a major role in driving the suppressive function of T regulatory (Treg) cells (Wing et al., 2008; Peggs et al., 2009).”
BackgroundA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Self-citationRegulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
“It was suggested that in BALB/c mice, known for their susceptibility to various immune-mediated disorders, the reduced suppression capacity of CTLA-4deficient Treg cells is due to their inability to downregulate CD80 and CD86 via transendocytosis (203, 205).”
BackgroundMethodFOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
“A recent study in mice has shown that CTLA4 is crucial for the suppressive function of FOXP3 + T Reg cells both in vitro and in vivo”
BackgroundSelf-citationCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
“(117) demonstrated that selective ablation of CTLA-4 in Tregs could cause systemic autoimmunity and fatal disease but did not alter Treg development or convert Tregs toward pathogenicity.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Self-citationBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Self-citationTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
“The function of CTLA-4 on Treg cells has been somewhat clarified by the recent demonstration that animals with a selective deletion of expression of CTLA-4 develop systemic autoimmunity at 7 weeks of age (Wing et al., 2008).”
InfluentialThe role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
“Furthermore, all three inhibitory molecules also contribute to cell-extrinsic regulation by controlling Treg homeostasis and function, mediating induced Treg development, and mitigating dendritic cell differentiation and function (13-16, 18, 19).”
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundAnti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
“Mice with Tregselective ablation of CTLA-4 recapitulate the majority of autoimmune phenotypes observed in traditional KO mice, including tissue-infiltrating T cells and damage to normal tissues and organs (71).”
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
“For example, regulatory T (Treg) cells with constitutive CTLA-4 expression can mediate CD80/86 downregulation on dendritic cells (DCs) through this trans-endocytosis process, which is required for the suppressive function of Treg cells.(73) As mentioned above, a cisCD80/PD-L1 heterodimer on APCs protects CD80 from CTL…”
BackgroundAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
BackgroundTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Foxp3+ follicular regulatory T cells control the germinal center response
Linterman, M. A., Pierson, W., Lee, S. K., Kallies, A., Kawamoto, S., Rayner, T. F., Srivastava, M., Divekar, D. P., Beaton, L., Hogan, J. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2425 · Cited by 1,292
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Self-citationRegulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
“Furthermore, and most importantly, mice lacking CTLA-4 specifically in T reg cells succumb to lymphoproliferation, a variety of autoimmune diseases, and hyperproduction of IgE, in a manner similar to Foxp3-deficient mic”
BackgroundSelf-citationTh17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Self-citationGuidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.012 · Cited by 955
“Coinhibitory molecules such as CTLA-4 and PD-1 not only serve as markers for T cell acti- vation but also contribute to Treg cell stability and function (Francisco et al., 2009; Wing et al., 2008), indicating that TIGIT+ Treg cells might be better equipped for mediating suppression.”
BackgroundRegulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Self-citationCancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
“CTLA4 contributes to Treg cell function by decreasing CD80 and CD86 expression on dendritic cells (Qureshi et al., 2011; Wing et al., 2008).”
BackgroundThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
“Lastly, recent evidence indicates that CTLA-4 is needed for the optimal function of regulatory T cells (Tregs) (31).”
BackgroundKumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
The microbiota regulates type 2 immunity through RORγt + T cells
Ohnmacht, C., Park, J.-H., Cording, S., Wing, J. B., Atarashi, K., Obata, Y., Gaboriau-Routhiau, V., Marques, R., Dulauroy, S., Fedoseeva, M., et al. (2015) · Science · doi:10.1126/science.aac4263 · Cited by 863
“FoxIRES-cre mice were crossed with CTLA-4-floxed mice (38).”
BackgroundSelf-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
“Tregs that are deficient for CTLA-4 have impaired suppressive ability (7), and antibodies that block CTLA-4 interaction with B7 can inhibit Treg function (8, 9).”
BackgroundRegulatory T cells: how do they suppress immune responses?
Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P., & Yamaguchi, T. (2009) · International Immunology · doi:10.1093/intimm/dxp095 · Cited by 854
Self-citationImmune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J.-N., Tran, D. Q., Stoddard, J., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 848
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
“CTLA-4 is an essential effector component of T reg cells that is required for their suppressive function 14-18 .”
Self-citationGenome-wide association study in alopecia areata implicates both innate and adaptive immunity
Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., Kim, H., Singh, P., Lee, A., Chen, W. V., et al. (2010) · Nature · doi:10.1038/nature09114 · Cited by 830
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
“As tumors with high T-reg infiltration are typically associated with poor prognosis (Shimizu et al., 2010), anti-CTLA4 therapy may benefit this population (Wing et al., 2008).”
BackgroundJeffery, L. E., Burke, F., Mura, M., Zheng, Y., Qureshi, O. S., Hewison, M., Walker, L. S. K., Lammas, D. A., Raza, K., & Sansom, D. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803217 · Cited by 789
“Recently, we have observed that CTLA-4-deficient Tregs have compromised function in a model of diabetes (63) and conditional deletion of CTLA-4 in Tregs has been shown to cause fatal autoimmunity (64).”
BackgroundmTORC1 couples immune signals and metabolic programming to establish Treg-cell function
Zeng, H., Yang, K., Cloer, C., Neale, G., Vogel, P., & Chi, H. (2013) · Nature · doi:10.1038/nature12297 · Cited by 788
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
“The most likely explanation for these differences is variation in the assay condition”
BackgroundPhenotypical and functional specialization of FOXP3+ regulatory T cells
Campbell, D. J., & Koch, M. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2916 · Cited by 773
“By contrast, loss of CTLA4 expression in T Reg cells resulted in severe lymphoproliferative disease characterized by massive lymphadenopathy and splenomegaly, and was associated with the accumulation of CD4 + CD44 hi FOXP3 − effector T cells, spontaneous multi-organ autoimmunity and early deat”
Molecular Mechanisms of Treg-Mediated T Cell Suppression
Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 761
“Strikingly, mice with Treg-specific ablation of CTLA-4 spontaneously develop fatal autoimmune disease (Wing et al., 2008), underlining the importance of CTLA-4 expression on Tregs for the maintenance of peripheral tolerance.”
BackgroundOhkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.010 · Cited by 754
Self-citationMetabolic coordination of T cell quiescence and activation
Chapman, N. M., Boothby, M. R., & Chi, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0203-y · Cited by 751
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
“There are multiple inhibitory mechanisms that suppress immune responses, including inhibitory receptors, secreted soluble inhibitors (IL-10 and TGF-β), and regulatory T cells (Tregs) (3, 16-17, 19-22).”
BackgroundHuman FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Self-citationRegulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Self-citationXu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., Dong, Z., Zhu, W., Peng, R., & Liu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00715 · Cited by 695
tTregs, pTregs, and iTregs: similarities and differences
Shevach, E. M., & Thornton, A. M. (2014) · Immunological Reviews · doi:10.1111/imr.12160 · Cited by 606
“Strong support in favor of this mechanism was derived from the demonstration that the deletion of CTLA-4 in Foxp3 Tregs resulted in the development of fatal T-cellmediated autoimmune disease (31).”
ResultCretney, E., Xin, A., Shi, W., Minnich, M., Masson, F., Miasari, M., Belz, G. T., Smyth, G. K., Busslinger, M., Nutt, S. L., et al. (2011) · Nature Immunology · doi:10.1038/ni.2006 · Cited by 605
“T reg cells exert their immunoregulatory functions through a variety of effector mechanisms, such as upregulation of the immune modulator CTLA-4 (refs”
BackgroundThe significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
“2 expression on DCs, thus affecting the capacity of APCs to activate conventional T cells (64).”
BackgroundRomano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
“(19, 20), postsort flow cytometric analysis confirmed that the vast majority Table 1.”
BackgroundFaria, A. M. C., & Weiner, H. L. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00280.x · Cited by 601
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
“6A) and CTLA-4 is important for the functions of T regs ( 37 ), the relationship between hypoxia and CTLA-4 ex-pressiononT regs wasfurtherevaluated.”
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00541-y · Cited by 597
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
“CTLA-4 has been described to be constitutively expressed on Treg cells (Read et al., 2000, 2006; Wing et al., 2008) and emerging data suggest this may also be relevant to Treg cells infiltrating human tumors (De Simone et al., 2016; Plitas et al., 2016).”
BackgroundTumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Self-citationTyagi, A. M., Yu, M., Darby, T. M., Vaccaro, C., Li, J.-Y., Owens, J. A., Hsu, E., Adams, J., Weitzmann, M. N., Jones, R. M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.013 · Cited by 564
“Among them is the capacity of Treg cells to blunt CD28 signaling (Wing et al., 2008).”
BackgroundTodd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.038 · Cited by 559
“(G) Percentage of KLRG1 CD103 Tregs (WT, n = 9; Il4i1 / , n = 6), and (H) of CTLA4+ Tregs was measured by flow cytometry (WT, n = 9; Il4i1 / , n = 6). n = number of mice.”
BackgroundInfluentialGATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice
Wohlfert, E. A., Grainger, J. R., Bouladoux, N., Konkel, J. E., Oldenhove, G., Ribeiro, C. H., Hall, J. A., Yagi, R., Naik, S., Bhairavabhotla, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57456 · Cited by 556
Development and maintenance of intestinal regulatory T cells
Tanoue, T., Atarashi, K., & Honda, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.36 · Cited by 553
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
“CTLA-4 has been shown to be critical for the maintenance of Treg suppressor function (35).”
BackgroundRetractedCD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
“…a direct mechanism involving transendocytosis (CTLA-4-mediated transfer of B7 molecules from the surface of the APC to inside the T cell), which reduces B7 availability on the APCs thereby reducing CD28 costimulatory signals (Qureshi et al., 2011; Immunity 44, May 17, 2016 959 Wing et al., 2008).”
Immune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541
Strazzulla, L. C., Wang, E. H. C., Avila, L., Lo Sicco, K., Brinster, N., Christiano, A. M., & Shapiro, J. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.04.1141 · Cited by 536
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Weiner, H. L., da Cunha, A. P., Quintana, F., & Wu, H. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01017.x · Cited by 535
“The CD4 cells from OVA TCR Tg fed animals had greater suppressive properties in vitro than natural Tregs, mediated suppression in part by both TGFb and IL-10, and induced increased expression of CTLA-4, a molecule known to be involved in Treg activity (79, 80).”
BackgroundEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
“[49] Wing, K.”
BackgroundContinuous requirement for the TCR in regulatory T cell function
Levine, A. G., Arvey, A., Jin, W., & Rudensky, A. Y. (2014) · Nature Immunology · doi:10.1038/ni.3004 · Cited by 521
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
“In the steady state, Treg cells use CTLA-4 to reduce the amounts of costimulatory proteins on DCs, thus inhibiting T cell activation and preventing autoimmunity (Qureshi et al., 2011; Wing et al., 2008).”
BackgroundRadiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Regulatory Lymphocytes and Intestinal Inflammation
Izcue, A., Coombes, J. L., & Powrie, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132657 · Cited by 507
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
“In 1996, James Allison found that blocking CTLA-4 caused tumor regression in mice.(148) In subsequent human studies, the CTLA-4 antibody ipilimumab was the first-in-class ICB agent to be tested in clinical studies.”
BackgroundTekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490
“For functional comparison with TL Tregs, CTLA-4 KO and WT CTLA-4–expressing Tregs were isolated from female CTLA-4, Foxp3 heterozygous, Rosa-RFP-reporter (CRF) mice on the BALB/c background, which harbored both WT and KO Tregs without developing spontaneous autoimmunity (5, 26).”
BackgroundMethodInfluentialSelf-citationPD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Targeting Treg cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 476
Self-citationResistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.